Last reviewed · How we verify
PRAX-562
At a glance
| Generic name | PRAX-562 |
|---|---|
| Sponsor | Praxis Precision Medicines |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) (PHASE2, PHASE3)
- A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRAX-562 CI brief — competitive landscape report
- PRAX-562 updates RSS · CI watch RSS
- Praxis Precision Medicines portfolio CI